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1 |  INTRODUCTION
The lamin intermediate filament (IF) proteins are the pri-
mary structural proteins of the nuclear lamina. Their nu-
merous functions include maintenance of nuclear shape 
and structure, transcription regulation, nuclear pore po-
sitioning, heterochromatin organization, and downstream 
pathways including differentiation, proliferation, and se-
nescence.1-3 Lamins are type V intermediate filament pro-
teins, subdivided into A and B types. Mutations in the genes 
encoding these proteins, the majority of which occur in 
LMNA (encoding lamin A/C), are associated with a group 
of rare heterogeneous diseases known as laminopathies. 
Laminopathies comprise a growing list of diseases with 
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Abstract
Laminopathies are rare diseases associated with mutations in LMNA, which encodes 
nuclear lamin A/C. LMNA variants lead to diverse tissue-specific phenotypes in-
cluding cardiomyopathy, lipodystrophy, myopathy, neuropathy, progeria, bone/skin 
disorders, and overlap syndromes. The mechanisms underlying these heterogeneous 
phenotypes remain poorly understood, although post-translational modifications, in-
cluding phosphorylation, are postulated as regulators of lamin function. We cata-
logued all known lamin A/C human mutations and their associated phenotypes, and 
systematically examined the putative role of phosphorylation in laminopathies. In 
silico prediction of specific LMNA mutant-driven changes to lamin A phosphoryla-
tion and protein structure was performed using machine learning methods. Some of 
the predictions we generated were validated via assessment of ectopically expressed 
wild-type and mutant LMNA. Our findings indicate phenotype- and mutant-specific 
alterations in lamin phosphorylation, and that some changes in phosphorylation may 
occur independently of predicted changes in lamin protein structure. Therefore, 
therapeutic targeting of phosphorylation in the context of laminopathies will likely 
require mutant- and kinase-specific approaches.
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diverse tissue-specific phenotypes, including cardiomyop-
athies, lipodystrophies, muscular dystrophies, neuropathies, 
premature ageing syndromes (progeria), and bone/skin 
disorders.
The phenotypic diversity and tissue-specific nature of 
the laminopathies have driven extensive investigation into 
the mechanisms underlying these diseases. Two nonmu-
tually exclusive putative mechanistic pathways have been 
postulated: (i) a “structural” pathway, whereby disrupted 
lamin protein structure leads to nuclear lamina fragility, 
possible nuclear deformation, and vulnerability to mechan-
ical stress; and (ii) a “gene expression” pathway, whereby 
protein-protein interactions, heterochromatin organization, 
and genome-lamina contacts are altered, leading to changes 
in downstream gene expression.2,4 The specific pathway in-
voked in each case is thought to depend on the location of 
the mutation within the structure of lamin A. Specifically, 
mutations in the helical rod domain tend to lead to cardio-
myopathy and muscular dystrophy (“structural” pathway), 
while mutations in the tail or immunoglobulin (Ig)-like do-
main are associated with lipodystrophy (“gene expression” 
pathway), although interplay between the pathways has 
also been surmised.4
Still, the precise mediators of these  invoked pathways, 
particularly in light of potential therapeutic approaches, re-
main poorly understood. There is increasing evidence that 
post-translational modifications (PTMs) in IF proteins, in-
cluding lamin A, have a major role in regulating their func-
tion, including structural aspects such as protein solubility 
and filament disassembly, as well as localization and part-
ner protein interactions.5,6 Phosphorylation, in particular, 
has a significant role in regulating lamin A function, both 
in physiologic and pathologic contexts. Classically, lamin 
A phosphorylation occurs during mitosis, resulting in dis-
assembly of the nuclear lamina.7,8 More recent studies have 
also identified roles for interphase lamin A phosphoryla-
tion,9 including in regulation of lamin localization and distri-
bution, protein-protein interactions, downstream signaling, 
and transcription.10
In the context of the laminopathies, available evidence 
primarily focuses on phosphorylation as part of a global 
stress response downstream of mutated lamin A. For exam-
ple, in the LMNAH222P/H222P dilated cardiomyopathy mouse 
model, upregulation of the c-Jun N-terminal kinase (JNK), 
extracellular signal-regulated kinase (ERK), and p38α mi-
togen-activated protein kinase (MAPK) branches of the 
MAPK pathway has been demonstrated.11,12 Furthermore, 
these stress-activated kinase pathways have shown prom-
ise as a therapeutic target: inhibitors of ERK1/2, JNK, and 
p38α have biochemical, phenotypic, and survival benefits 
in animal studies.13-17 In addition, the mammalian target 
of rapamycin (mTOR) kinase pathway, involved in such di-
verse cell functions as growth and proliferation, survival, 
and autophagy, has been implicated as a therapeutic target 
in lamin mutation-driven models of cardiomyopathy18 and 
progeria.19
In contrast, studies of direct lamin A phosphorylation 
and its potential role in laminopathies have been sparse. One 
study on phosphorylation in patients with Emery-Dreifuss 
muscular dystrophy (EDMD) versus healthy controls noted 
significantly decreased N-terminal phosphorylation of lamin 
A in muscle cells of individuals with EDMD, with phosphor-
ylation being similar between groups in fibroblasts.20 In addi-
tion, the myopathy-associated mutations in the Ig-fold motif 
of lamin A have been associated with increased S458 phos-
phorylation, which is not present in other laminopathy types 
or in normal healthy controls.21
To more comprehensively explore the precise roles of 
phosphorylation in the laminopathies, we compiled available 
data on all reported LMNA mutations with their associated 
phenotypes, as well as readily available clinical metadata 
such as sex and geographic origin. We subsequently per-
formed in silico prediction of specific LMNA mutant-driven 
alterations in lamin A phosphorylation and protein structure. 
We then validated the in silico predictions using in vitro 
assessment of ectopically expressed wild-type and mutant 
LMNA phosphorylation. Our findings suggest disease- and 
mutant-specific alterations in lamin phosphorylation, and that 
some changes in phosphorylation may occur independently 
of predicted changes in lamin protein structure. Therefore, 
therapeutic targeting of phosphorylation in the context of 
laminopathies may require a mutant- and kinase-specific 
approach.
2 |  MATERIALS AND METHODS
2.1 | Data collection
LMNA mutation and phenotypic data were obtained from 
publicly available databases: the Human Intermediate 
Filament Database,22 the Universal Mutation Database 
(www.umd.be/LMNA), and the UniProt Knowledgebase.23 
Two additional reported mutations were provided by lit-
erature review of PubMed spanning 2017-2018.24,25 When 
available, additional clinical data were also collected, in-
cluding patient sex and geographic origin. Additional non-
synonymous benign variant data were obtained from the 
Exome Aggregation Consortium (ExAC).26 The workflow 
including data collection and computational analysis is 
summarized in Figure 1. Additional data regarding domain 
assignment (start and end of lamin A domains) were ob-
tained from UniProt.23 It should be noted that there is a 
lack of consensus in the literature regarding the residue 
position at which each domain starts and ends, given the 
variations in domain position assignment.22,23,27-29 For our 
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analyses, we utilized UniProt’s domain designations con-
sistently throughout. Importantly, there is inconsistency 
regarding the subdivision of coil 2 (into 2A, Linker 2, and 
2B); based on recent description by Herrmann and Aebi,30 
we did not subdivide coil 2. Alignment of heptad repeats 
was performed using pooled studies.23,27,28,31
F I G U R E  1  Schematic demonstrating overall workflow including source data acquisition, compilation, and analysis. 404 unique 
mutations were identified (encompassing 1890 individuals), of which 399 were associated with disease. 1619 out of the 1890 total individuals 
had documented disease - notably, some individuals with disease-associated mutations were documented as "asymptomatic".
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2.2 | Protein structure and 
functional prediction
The predicted mutational effects on protein structure and 
subsequent effects on function were performed using 
well-established and previously published software tools: 
MutPred2,32 Sorting Intolerant from Tolerant (SIFT),33 and 
Polymorphism Phenotyping v2 (PolyPhen-2).34 MutPred2 
is a machine-learning–based method that integrates several 
protein parameters including metal binding, structural sta-
bility, protein binding, PTMs, and DNA binding into its 
prediction algorithm. Meanwhile, SIFT and PolyPhen-2 
rely on sequence homology and predicted alterations to 
protein structure in their algorithms. A “consensus predic-
tion” between the three tools was obtained by identifying 
predicted protein disruptions that were consistent among 
all three tools with the highest confidence. The purpose of 
this was to eliminate potential effects on protein function 
due to predicted PTM alterations (only in MutPred2) and to 
minimize false positives, as computational tools have been 
shown to lack specificity in predicting significant protein 
disruption.35
2.3 | Phosphorylation prediction
Changes in lamin A phosphorylation due to mutational ef-
fects were predicted using two previously validated tools: 
(i) MIMP  (Mutation IMpact on Phosphorylation), a ma-
chine-learning algorithm developed originally for cancer 
networking analysis,36 and (ii) MusiteDeep, a deep-learning 
algorithm that takes raw sequence data as input and uses con-
volutional neural networks to predict mutational impacts.37 
MIMP works by constructing specificity models for kinases, 
which are then used to score phosphosites containing a mu-
tation before and after the mutation to predict the impact it 
may have on phosphorylation.36 Training data for these al-
gorithms were acquired from PhosphoELM,38 PhosphoSite 
Plus,39 HPRD,40,41 and PhosphoNetwork.42 A consensus 
score, like the protein structural and functional prediction 
above, was created to minimize false positives.
In contrast to MIMP, MusiteDeep does not have a native al-
gorithm to identify changes between native and mutant protein 
phosphorylation. Thus, native and mutant protein phosphory-
lation predictions were determined separately for each kinase 
(CDK, PKC, PKA, MAPK, CK2, and Other—encompassing 
all other trained kinases) via input of an amino acid sequence. 
The resulting predicted phosphorylation scores (represented as 
a probability between 0 and 1) were then compared between 
the specific mutant sequence and the native sequence, and an 
overall likelihood of change (loss or gain) was determined via a 
z-score calculation (difference between mutant and native like-
lihood of phosphorylation divided by the standard deviation of 
phosphorylation scores in the native sequence). A |z-score| >= 
1 was determined to be a probable change in phosphorylation 
status, as long as either the mutant or native absolute score 
was >= 0.5 (threshold indicating that there is probable phos-
phorylation). As an example, if the standard deviation of native 
sequence MusiteDeep scores is 0.25, only a change of >= 0.25 
with at least one of the mutant or native values >= 0.5 overall 
would yield a predicted change in phosphorylation.
2.4 | Consensus scoring
A consensus score was calculated for both protein struc-
tural/functional and phosphorylation predictions. For pro-
tein structure/function, SIFT, PolyPhen-2, and MutPred2 
were utilized for prediction. For each of these tools, there 
are different levels of confidence for each prediction. For 
SIFT, the native score assigns a “significance” between 0 
and 1, and <0.1 was assigned a score of 1 (for “possible” 
damage) and <0.05 was assigned a score of 2 (“probable” 
damage). For PolyPhen-2, the HumDiv-trained model was 
used, with 10% false-positive rate (fpr) given a score of 
1 and 5% fpr given a score of 2. Finally, for MutPred2, a 
threshold of 0.68 (yields a fpr of 10%) was given a score of 
1, and 0.80 (fpr 5%) was given a score of 2. These scores 
were summed (for a maximal score of 6), then converted 
into a consensus score between 0 and 1 (0-2 = 0; 3-4 = 0.5; 
5-6  =  1). For phosphorylation prediction, a predicted 
change as indicated by either MIMP or MusiteDeep yielded 
a score of 1 (no change = 0). These 2 predictions were then 
converted into a consensus score between 0 and 1 (ie, nei-
ther predicting a change = 0, one predicting change = 0.5, 
and both predicting change = 1).
2.5 | Hotspot analysis
To systematically and statistically define hotspots, the R 
package DominoEffect was utilized.43 DominoEffect uses a 
poisson distribution to systematically identify hotspots given 
a set of parameters such as window (length of peptide se-
quence considered) and threshold (the minimum proportion 
of total mutations represented by a single mutation). Hotspots 
were defined according to disease phenotype (eg, hotspots 
for lipodystrophy were determined only using mutations as-
sociated with lipodystrophy).
2.6 | Protein structure modeling
The protein structural predictions were supplemented with 
modeling and visualization of select mutations via DynaMut.44 
Since there is no complete crystal structure of lamin A/C, 
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fragments including part of the globular tail domain and the 
coiled-coil domain were used. Protein Data Bank (PDB) files 
were obtained from the Research Collaboratory for Structural 
Bioinformatics PDB.45 The PDB 1IFR was used for the glob-
ular tail domain,46 and PDB 6JLB was used for the coil 2 of 
the rod domain.28
2.7 | Plasmids, transfection, and cell 
culture conditions
Human LMNA open-reading frame was purchased from 
Origene (Rockville, MD) and subcloned into the pCMV6 vector 
with amino-terminal myc/DDK tag (Origene) as described.47 
LMNA mutants were generated using the QuikChange II site-
directed mutagenesis kit (Agilent Technologies, Santa Clara, 
CA). Lipofectamine-2000 (Life Technologies, Carlsbad, CA) 
was used for transfection of human hepatoma Huh7 cells 
(American Type Culture Collection, Manassas, VA), which 
were maintained at 37°C, 5% CO2, and plated at ~70% conflu-
ency 1 day prior to transfection. Where indicated, cells were 
treated with 500  nM okadaic acid (Cayman Chemical, Ann 
Arbor, MI) for 1 hour prior to harvest.
2.8 | Cell lysis and SDS-PAGE
Cells were solubilized in Triton lysis buffer (1% Triton X-100, 
50 mM Tris pH 8.0, 150 mM NaCl, and protease inhibitor cocktail 
(Sigma-Aldrich, St. Louis, MO)) or RIPA lysis buffer (50 mM 
Tris pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS, and protease inhibitor cocktail) as indicated. 
Where indicated, phosphatase inhibitors were added to lysis 
buffer: 1 mM sodium orthovanadate, 1 mM β-glycerophosphate, 
and 1 mM NaF. After centrifugation (12 000 ×g, 10 minutes, 
4°C), the supernatant protein concentration was determined 
(bicinchoninic acid assay, Thermo Fisher, Waltham, MA). The 
supernatant was then used for immunoprecipitation of tagged 
LMNA or diluted in Novex 2X Tris-glycine sample buffer with 
SDS (Invitrogen, Carlsbad, CA) with 2% β-mercaptoethanol for 
SDS-PAGE. For solubility experiments, the Triton-insoluble 
pellet was solubilized in SDS-containing sample buffer (95°C, 
5 minutes). Proteins were resolved using 4%-20% Novex Tris-
glycine gels (Invitrogen) and visualized by immunoblotting or 
Coomassie staining.
2.9 | Immunoprecipitation and 
immunoblotting
Two days after transfection with myc/DDK-tagged LMNA, 
Huh7 cells were solubilized in RIPA lysis buffer (4°C, 
30  minutes), and tagged LMNA was immunoprecipitated 
using pooled anti-myc (Abcam, Cambridge, MA) and anti-
FLAG (Sigma-Aldrich) antibodies and Dynabeads protein 
G (Invitrogen). Beads were washed with RIPA buffer fol-
lowed by PBS, then stored at 4°C prior to in vitro kinase 
assay. For immunoblot analysis, lysates were resolved via 
SDS-PAGE and transferred to polyvinylidene fluoride 
membranes (Bio-Rad, Hercules, CA) for immunoblotting. 
Where indicated data were quantified by densitometry using 
ImageJ version 1.52a.
2.10 | In vitro kinase assays
The p38 kinase assay was performed per manufacturer guide-
lines (R & D Systems, Minneapolis, MN). Briefly, 100 ng re-
combinant p38α (R & D Systems; diluted to 10 ng/µL in 5 mM 
MOPS, pH 7.2, 5 mM MgCl2, 1 mM EGTA, 0.4 mM EDTA, 
0.05 mM DTT, 2.5 mM β-glycerolphoshate, and 40 ng/mL 
BSA) was added to beads with immunoprecipitated LMNA. 
Subsequently, 5 µL of water was added followed by 5 µL of 
[γ-32P] ATP assay cocktail (0.5µ Ci/µL [γ-32P]ATP (Perkin 
Elmer, Waltham, MA), 0.1 mM ATP, 25 mM MOPS pH 7.2, 
25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 0.25 mM DTT, 
and 12.5 mM β-glycerophosphate), and the reaction was in-
cubated at 30°C for 30 minutes. The PKCα kinase assay was 
performed as described.48 Briefly, beads with immunopre-
cipitated LMNA were incubated with 50 ng PKCα (Abcam) 
and 5 µCi of [γ-32P]ATP (30°C, 30 minutes) in PKCα kinase 
buffer (20 mM Tris pH 7.5, 5 mM MgCl2, 0.2 mM CaCl2, 
5  µg/mL phosphatidylserine, 0.5  µg/mL diolein, and 5  µM 
ATP). Kinase reactions were stopped by adding Laemmli 
buffer and heating (95°C  <  4  minutes), then resolved via 
SDS-PAGE followed by autoradiography. Quantitation was 
performed by densitometry using ImageJ version 1.52a.
2.11 | Statistical analysis
Statistical significance for comparisons of categorical distribu-
tion (eg, domain) among phenotypes was performed using χ2 
and Fisher’s exact tests (depending on the number of zero or 
low values). Hotspot versus non-hotspot comparisons were an-
alyzed with a two-proportions test. Hierarchical clustering and 
heatmap construction were performed by ComplexHeatmap.49 
Numerical comparisons (eg, likelihood score for phosphoryla-
tion change) were analyzed using nonparametric tests including 
Mann-Whitney and Kruskal-Wallis tests given lack of normal-
ity assumption (ordinal variables). Multiple comparisons were 
corrected for using the false discovery rate (FDR) method. 
For biochemical assays, two-tailed Student’s t-test or paired 
ANOVA (Friedman test) followed by multiple comparison ad-
justment using uncorrected Dunn’s test was used, as indicated. 
These tests were implemented using R and GraphPad Prism.
9056 |   LIN et aL.
3 |  RESULTS
3.1 | Mutational patterns in the LMNA gene
To identify mutational patterns associated with the laminopa-
thies, all available data on LMNA mutations were collected 
from publicly available databases and the medical literature 
(see Materials and Methods). Comprehensive raw mutational 
and clinical data are compiled in Supplemental Data 1. In 
total, 399 disease-associated mutations encompassing 1619 
individuals were identified (Figure 2A), with an additional 5 
mutations (not included in the 1619 total) recorded in available 
repositories that did not have a clear associated disease pheno-
type. Demographics of these 1619 patients are summarized in 
Table 1. The distribution of mutations and hotspots appeared 
to differ by phenotype (Figure 2A). Of these disease-associ-
ated mutations, 369 (92.5%) were within coding regions of 
the LMNA gene and 30 were intronic. There were 277 (75.1%) 
F I G U R E  2  Observed disease-associated mutational patterns in LMNA. A, Map depicting all known LMNA mutations distributed along the 
lamin A backbone (top: yellow bar depicts mature lamin A backbone, with the hashed-CaaX portion indicating preprocessed prelamin A). Black 
bars depict the positions of known mutations by phenotype, scaled in intensity by increasing number of individuals at that particular position. Taller 
red bars indicate identified hotspots via DominoEffect by phenotype. B, Summary of observed mutations in coding and noncoding (intronic) regions 
of LMNA (left), then subdivided by mutation type (right). Missense mutations are the most common LMNA mutation. C, Sex distribution differs 
significantly by phenotype (χ2 = 79.58, df = 5, P < .0001). D, The distribution of mutation type differs significantly by phenotype (χ2 = 235.4, 
df = 10, P < .0001). E, Mutations fall into different lamin A functional domains, depending on phenotype. There is a significant difference 
observed between groups (χ2 = 513.0, df = 10, P < .0001). F, Distribution of mutation status (heterozygosity vs homozygosity) varies significantly 
by phenotype (Fisher’s exact test, simulated with B = 1.0e + 07: P < .0001)
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coding region missense mutations, with the remainder com-
prising other types of mutations such as frameshift, nonsense, 
and deletion/insertion (Figure  2B). Notably, missense muta-
tions occupied a larger proportion of disease-associated LMNA 
mutations compared to what had been previously observed in 
the Human Gene Mutation Database,50 a global analysis of all 
known (>200 000) disease-associated mutations in the human 
genome (Supplemental Figure 1).
3.2 | Sex and geographic distribution differ 
by phenotype
Significant differences in the distribution by sex were ob-
served among phenotypes (Figure 2C). Specifically, lipod-
ystrophy and metabolic disorders showed a female-skewed 
sex distribution, which was also observed in the overlap 
group. Males were relatively overrepresented in the neurop-
athy group. Meanwhile, relatively equal male-female distri-
bution was observed in the other phenotypes. In contrast to 
the human situation, hepatocyte-specific null mice show a 
male predominance of developing spontaneous fatty liver 
disease as the mice age, and marked predisposition to steato-
hepatitis and fibrosis when challenged with a high fat diet.51
Available data on geographic origin showed that most 
reported disease originated in Europe (Supplemental Table 
1). The neuropathy phenotype, driven by those with Charcot-
Marie-Tooth disease, mostly originated in Africa and was vir-
tually absent from other geographic regions. The Americas 
showed a greater than expected number of patients with pro-
geria. The precise geographic origin among individuals with 
lipodystrophy was frequently not reported.
3.3 | Phenotypic association with mutation 
type, protein domain, and heterozygosity
In our comprehensive analysis of all available laminopathy 
genotype and phenotype data, striated muscle laminopathies 
(affecting either cardiac or skeletal muscle) and premature 
aging syndromes were associated with a greater proportion of 
non-missense (“other”) and intronic mutations than other phe-
notypes (Figure 2D). In contrast, lipodystrophies, neuropathies, 
and bone/skin diseases were dominated by missense mutations.
Furthermore, striated muscle laminopathies and neurop-
athies were predominantly driven by mutations in the rod 
domain, while lipodystrophies, disorders affecting bone 
and skin [mandibuloacral dysplasia (MAD)], and premature 
aging syndromes were generally associated with mutations 
affecting the tail domain (Figure 2E). Overlap syndromes (a 
single individual with two or more documented phenotypes, 
eg, dilated cardiomyopathy and lipodystrophy simultane-
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Laminopathy patients were most likely to have heterozy-
gous LMNA mutations, with a small portion (25/1619 = 1.5%) 
demonstrating compound heterozygosity. Intriguingly, pa-
tients with Charcot-Marie-Tooth (CMT) neuropathy and 
mandibuloacral dysplasia were predominantly homozygous 
for their associated mutations (Figure 2F)—driven mostly by 
their hotspots, R298C and R527H, respectively.
3.4 | Disease-associated mutations 
frequently occur at specific amino acid 
residues and locations
Most commonly, disease-associated mutations resulted in a 
loss of a native arginine followed by leucine, glutamic acid, 
and alanine (Figure 3A). These most frequently led to a gain 
of proline, lysine, cysteine, histidine, and valine (Figure 3A). 
When these changes were correlated with phenotype, the loss 
of a native leucine, glutamate, or alanine most frequently led 
to a striated muscle laminopathy phenotype, whereas loss of 
arginine uniquely led to a disproportionate number of patients 
with a lipodystrophy and neuropathy phenotype (Supplemental 
Figure 2A). Meanwhile, loss of proline almost exclusively led 
to a striated muscle laminopathy phenotype, while gain of va-
line, histidine, or cysteine resulted in more heterogenous dis-
ease manifestations (Supplemental Figure 2B).
We then considered how these mutations localized, particu-
larly as it pertains to lamin dimer and tetramer formation, which 
may be adversely affected by mutations in the coiled-coil rod do-
main. Comprising this coiled-coil are a series of heptad repeats 
(Figure  3B), which allow for stabilizing interactions between 
monomers. Notably, disease-associated mutations are found more 
frequently in the e and g positions of the heptad repeat, which 
commonly form an oppositely charged ion pair (Figure 3C). We 
then analyzed the phenotypes with the most mutations in the rod 
domain and noted distinct patterns in mutation frequency per 
position in the heptad repeat (Figure 3D). In particular, dilated 
cardiomyopathy with conduction disease (DCM-CD) had rela-
tive parity among 6/7 heptad positions, whereas limb-girdle mus-
cular dystrophy type 1b (LGMD1B), LMNA-related congenital 
muscular dystrophy (L-CMD), and Emery-Dreifuss muscular 
dystrophy (EDMD) showed a predominance of mutations at the 
e position. Similarly, the overlap syndrome DCM-CD and famil-
ial partial lipodystrophy (FPLD) showed a pattern like the other 
skeletal muscular dystrophies and not DCM-CD alone.
3.5 | Hotspot mutations account for a 
majority of patients with laminopathy
Hotspot mutations, residues with particularly high mutation 
rates, are distributed throughout the entire protein, but were 
found to cluster by phenotype (Figure 2A). There were 35 total 
hotspot residues encompassing 968/1619 (60%) patients with 
laminopathies (Figure 4A). When associated with phenotype, 
hotspots formed 3 primary clusters, driven largely by the pres-
ence of either predominant adipose and cardiac involvement, 
predominant cardiac involvement, or relatively equal cardiac 
and skeletal muscle involvement (Figure 4A). Hotspots primar-
ily affected charged or nonpolar native amino acid residues 
(31/35 = 94%), with arginine being the most commonly affected 
residue (16/35 = 46%). Relative to non-hotspot mutations, hot-
spots were most often driven by C to T transition mutations 
(Figure  4B). Of missense mutations, analysis of amino acid 
transitions in hotspots vs non-hotspots revealed that hotspots 
were more commonly driven by native arginine residues mu-
tated to a noncharged amino acid residue, while non-hotspots 
were more frequently leucine to proline mutations (Figure 4C).
3.6 | LMNA mutations can lead to 
overlapping phenotypes in certain individuals
Several mutations were found to affect multiple organ sys-
tems. There were 42 mutations leading to overlap syndromes 
(Figure  5A), in which a single individual had multiple in-
volved organ systems (eg, both lipodystrophy and cardiomy-
opathy in a single patient). To identify phenotypic patterns 
among these mutations, hierarchical clustering was per-
formed, revealing at least 6 distinct clusters. These clusters 
varied largely by the relative dominance (or lack thereof) of 
a single or pair of phenotypes. For example, cluster 1 was 
driven by the R482W familial partial lipodystrophy (FPLD) 
hotspot, which was found to only occasionally overlap with a 
limb girdle muscular dystrophy (LGMD) phenotype. Cluster 
2 was driven by the CMT hotspot, R298C, with occasional 
striated muscle involvement. Cluster 3 demonstrated strong 
striated muscle involvement, with rare overlap of a lipodys-
trophy phenotype. Cluster 4 was characterized by a predomi-
nant lipodystrophy phenotype with relatively isolated bone/
skin or cardiac disease. The remaining clusters demonstrated 
relatively equal overlap between organs—cluster 5 showed a 
consistent lipodystrophy phenotype with varying degrees of 
striated muscle involvement, while cluster 6 showed a per-
sistent striated muscle phenotype combined with either neu-
ropathy or progeroid syndromes.
3.7 | Single LMNA mutations can lead to 
multiple disparate phenotypes
In addition to the overlap syndromes, 16 mutations were found 
to lead to separate, disparate phenotypes, such that certain in-
dividuals had a phenotype affecting one organ system, while 
others with the same mutation had phenotypes affecting a dif-
ferent organ in a nonoverlapping manner (eg, some patients 
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with isolated cardiac disease, others with isolated neuropathy). 
To identify phenotypic patterns among these mutations, hier-
archical clustering was again performed, revealing 4 primary 
clusters (Figure 5B). Clusters 1 and 2 were driven by hotspots. 
First, the G608G splicing Hutchinson-Gilford progeria syn-
drome (HGPS) hotspot mutation was noted to separately lead 
F I G U R E  3  Patterns of lost or gained amino acids in disease-associated missense mutations. A, Shown are the absolute number of changes by 
amino acid residue (bars), with native (black) residues indicating those that are lost as a result of mutation, while mutant (gray) residues represent 
those that result from mutation. Specific residues are highlighted in red (loss) or blue (gain) if the absolute difference between native and mutant 
is at least 10. Residues are grouped as charged, polar, nonpolar aliphatic, or aromatic (left to right). B, Schematic of coiled-coil dimerization 
based on heptad repeats, with example heptad from lamin A (residues 106-112), constructed with R package helixvis.73 Residues lettered a-g 
represent positions within the heptad, with colors highlighting charge or polarity (red: negative charge, blue: positive charge, yellow: neutral 
polar). C, Frequency of patients with mutations at a location within the rod domain corresponding to a heptad repeat, by position within the heptad. 
There is a significant difference among a-g (χ2 goodness-of-fit test: χ2 = 222.0, df = 6, P < .0001). D, Heatmap displaying phenotypes with at 
least 10 mutations corresponding to a heptad repeat. The color scale represents the number of patients with that phenotype that have a mutation 
corresponding to positions a-g within a heptad. DCM-CD, dilated cardiomyopathy with conduction disease; AR-CMT2, autosomal recessive 
Charcot-Marie-Tooth neuropathy type 2; LGMD1B, limb-girdle muscular dystrophy type 1B; L-CMD, LMNA-related congenital muscular 
dystrophy; FPLD, familial partial lipodystrophy; EDMD, Emery-Dreifuss muscular dystrophy
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F I G U R E  4  Hotspot mutations are associated with specific phenotypes and are driven by certain nucleotide and amino acid changes.  
A, Heatmap showing hotspot mutations identified via DominoEffect and the relative number of individuals with involvement of each organ system/
phenotype. B, Heatmap depicting differences in the proportion of total mutations in each group (hotspot vs non-hotspot) represented by each 
specified nucleotide base change. There was a significant difference in C to T transition mutations favoring hotspot mutations (Two-proportions 
test, hotspots vs non-hotspots: 0.3279 vs 0.1347, adjusted P = .0087). C, Heatmap depicting the proportion of total missense mutations per 
group (hotspot vs non-hotspot) represented by each amino acid mutation. There were no significant individual amino acid changes after P-value 
correction for multiple testing. However, when grouped, mutations involving native arginine residues were found to be highly significant favoring 
hotspots (Two-proportions test, hotspots vs non-hotspots: 0.592 vs 0.202, adjusted P < .0001), and mutations involving native leucine residues 
approached significance favoring non-hotspots (Two-proportions test, hotspots vs non-hotspots: 0 vs 0.145, adjusted P = .095)
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F I G U R E  5  LMNA mutations can be pleiotropic, sometimes causing overlapping phenotypes, disparate individual phenotypes, or both. 
A, Heatmap displaying mutations leading to overlap syndromes (multiple organ system involvement in the same individual), with the relative 
involvement of each organ system/phenotype. Hierarchical clustering was performed on the mutations, demonstrating 6 distinct clusters, which are 
labeled. B, Heatmap depicting mutations leading to multiple, disparate syndromes (distinct organ involvement in different individuals), with the 
relative involvement of each organ system/phenotype. Hierarchical clustering was performed on the mutations, demonstrating 4 distinct clusters, 
which are labeled. C, Heatmap depicting mutations found in both (A) and (B), representing mutations that can lead to overlapping and multiple 
disparate phenotypes, with relative involvement of each organ system
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to a full progeroid syndrome vs relatively isolated skin in-
volvement (restrictive dermopathy). Second, the R298C CMT 
hotspot led to either neuropathy or isolated cardiac disease. 
Cluster 3 included mutations associated with a range of phe-
notypic groups, without a dominant phenotype, while cluster 
4 showed predominantly striated or cardiac muscle with lipo-
dystrophy phenotypes.
3.8 | Certain LMNA 
mutations are associated with both 
overlapping and disparate phenotypes
Seven mutations (6 missense, 1 nonsense) were associ-
ated with both overlapping and disparate phenotypes 
(Figure  5C). Other than the R298C CMT hotspot, dis-
cussed above, and the R28W hotspot, which is associated 
with both lipodystrophy and striated muscle disease, these 
mutations were characterized by involvement of at least 
3 organ systems. Interestingly, the R644C mutation was 
found to encompass all known major organ phenotypes 
of the laminopathies, other than isolated bone or skin 
disease.
3.9 | Disease-associated mutations are 
predicted to alter lamin phosphorylation
To explore the mechanistic basis of the genotype-phe-
notype correlation in the laminopathies, we utilized a 
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machine-learning–based, computational approach to predict 
the direct impacts of specific missense mutations on lamin 
phosphorylation (see Materials and  Methods for details on 
the tools used). As a control, “benign” variants lacking se-
vere pediatric disease were obtained from the ExAC data-
base. Relative to control, disease-associated mutations were 
predicted to be more likely to disrupt lamin phosphorylation 
(Figure 6A). This was largely driven by a relative loss of phos-
phorylation (eg, destruction of a kinase motif), while predicted 
gains in phosphorylation were rare and did not differ between 
pathogenic and benign groups (Supplemental Figure 3A). 
Predicted changes in phosphorylation were mostly associated 
with mutations in the head or tail domains of the lamin A/C 
protein, with a relative paucity in the rod domain (Figure 6B).
3.10 | Predicted lamin phosphorylation 
changes are associated with phenotype, 
hotspots, and penetrance
Certain phenotypes were associated with a greater likelihood 
of predicted phosphorylation changes. Lipodystrophy, neu-
ropathy, and bone/skin groups were associated with a signifi-
cantly increased likelihood of lamin phosphorylation change 
than the benign group (Figure  6C). Striated muscle lami-
nopathies, in contrast, were associated with fewer predicted 
phosphorylation changes than benign variants (Figure  6C). 
These changes were driven largely by predicted loss of phos-
phorylation in the lipodystrophy, neuropathy, and bone/skin 
groups (Supplemental Figure 3B).
Hotspot mutations were significantly more likely to be 
predicted to cause a change in lamin phosphorylation than 
other, non-hotspot mutations (Figure 6D). Interestingly, de-
creased phenotype penetrance appeared to correlate specif-
ically with a predicted loss of phosphorylation (Figure 6E).
In total, the phosphorylation prediction tools we utilized 
agreed on 207/277 (74.7%) mutations. They agreed on a 
phosphorylation change on 30 mutations, with complete 
agreement on the putative kinase family involved on 28 mu-
tations (Supplemental Table 2). Notably, the most commonly 
lost kinase motif belonged to protein kinase C (PKC), with 
other lost motifs including protein kinase A (PKA), cyclin-de-
pendent kinase (CDK), MAPK, and casein kinase 2 (CK2). 
Hotspots for CMT, FPLD, and MAD (R298C, R482W/Q/L, 
R527C/H) were all specifically associated with a predicted 
loss of PKC-mediated phosphorylation. The most commonly 
gained motifs were kinase families CDK and MAPK—both 
invoked by the same mutations—with other gained kinase 
motifs including PKA, Akt, and CK2.
3.11 | Disease-associated mutations are 
predicted to alter protein structure
To investigate the possibility of alternative mechanisms 
of disease, we used several well-established computa-
tional tools (MutPred2, SIFT, and PolyPhen-2) to predict 
the impact of missense mutations on protein structure, 
folding, and function. Some select mutations were also 
modeled using DynaMut to further verify protein struc-
tural changes (Supplemental Figure 4). When compared to 
benign variants from the Exome Aggregation Consortium 
(ExAC) database, disease-associated mutations were sig-
nificantly more likely to be associated with predicted 
F I G U R E  6  Predicted LMNA mutation-driven phosphorylation and protein structural changes are associated with disease. A, Relative 
to variants restricted to asymptomatic individuals, disease-associated mutations have a significantly increased association with predicted 
phosphorylation changes (left, Mann-Whitney test: P = .0004) and protein structural changes (right, Mann-Whitney test: P < .0001), by likelihood 
score (see Materials and Methods). B, Left: Predicted phosphorylation changes are more likely in head and tail domains than the rod domain 
(Kruskal-Wallis test: P < .0001; Dunn’s multiple comparisons test: head vs rod, adjusted P = .001; head vs tail, adjusted P = .002; tail vs rod, 
adjusted P < .0001). Right: Predicted changes in protein structure are associated with specific lamin domains (Kruskal-Wallis test: P < .0001; 
Dunn’s multiple comparisons test: rod vs tail, adjusted P < .0001). C, Left: Predicted changes in phosphorylation differ by phenotype (Kruskal-
Wallis test: P < .0001). Striated laminopathies had significantly fewer predicted phosphorylation changes relative to the benign, asymptomatic 
ExAC group (Dunn’s multiple comparisons test: adjusted P = .013). Lipodystrophy/metabolic disease, neuropathy, and bone/skin disease had 
significantly greater predicted phosphorylation changes compared to the benign group (Dunn’s multiple comparisons test: lipodystrophy vs benign, 
adjusted P < .0001; neuropathy vs benign, adjusted P < .0001; bone/skin vs benign, adjusted P < .0001). Right: Predicted changes in protein 
structure differ by phenotype (Kruskal-Wallis test: P < .0001). Striated laminopathies and neuropathies had significantly greater predicted protein 
structural changes relative to the benign ExAC group (Dunn’s multiple comparisons test: striated vs benign, adjusted P < .0001; neuropathy vs 
benign, adjusted P < .0001). D, Hotspots were associated with a greater degree of predicted phosphorylation changes compared to non-hotspot 
mutations (Mann-Whitney test: P < .0001), but the same pattern was not observed in predicted protein structural changes (Mann-Whitney test: 
P = .7897). E, Left: Penetrance (defined as the percentage of individuals with a specific variant that carry any disease) is associated with predicted 
phosphorylation status (eg, loss or gain of phosphorylation) (Kruskal-Wallis test: P = .009). This was specifically driven by a difference in the 
group predicted to lose phosphorylation, which was associated with decreased penetrance (Dunn’s multiple comparisons test: loss vs no change, 
adjusted P = .005). Right: Penetrance is associated with predicted likelihood of protein structural changes (Kruskal-Wallis test: P = .0004). This 
was specifically driven by a difference between the unlikely group (score = 0) and the likely group (score = 1) (Dunn’s multiple comparisons test: 
unlikely vs likely, adjusted P = .0002)
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structural changes (Figure  6A). In addition, prediction 
of altered protein structure was predicted to be signifi-
cantly more likely in the rod domain relative to the tail 
(Figure 6B), although there was no significant difference 
between the rod and head domains. Striated laminopathies 
and neuropathy were both associated with an increased 
likelihood of altered protein structure relative to the be-
nign group (Figure 6C), but notably this was not seen in 
other phenotypes. In contrast to phosphorylation predic-
tions, predicted structural change was not more likely to 
segregate with hotspot mutations (Figure  6D). Predicted 
protein structural changes were associated with disease 
penetrance, with higher likelihood of change associated 
with higher penetrance (Figure 6E).
3.12 | Predicted lamin phosphorylation and 
structural changes independently associate 
with phenotype
When predicted protein structural changes were compared to 
predicted phosphorylation changes, no significant correlation 
was observed (Figure 7A). There was significant discordance 
(Figure  7B), such that mutations tended to be predicted to 
induce either structural or phosphorylation changes, but not 
both. Intriguingly, different phenotypes had different patterns 
of predicted effects on phosphorylation and protein struc-
ture (Figure  7C,D). While striated laminopathies primarily 
showed a relative dominance of protein structural changes, 
lipodystrophy and bone/skin diseases showed a large propor-
tion of individuals with predicted changes in phosphoryla-
tion. Interestingly, patients with neuropathy (mostly hotspot 
R298C) were predicted to have both protein structural and 
phosphorylation changes as a result of their mutation.
3.13 | Selected lamin mutants demonstrate 
changes in phosphorylation in vitro
To further explore the effects LMNA mutation on phospho-
rylation as suggested by in silico prediction, we used site-
directed mutagenesis to generate LMNA-variant constructs 
for selected hotspot mutations: T10I, R60G, and R482Q. 
We transiently transfected human hepatoma Huh7 cells with 
wild-type (WT) or mutant LMNA and performed an in vitro 
kinase assay using immunoprecipitated WT or mutant lamin 
A as substrate. Notably, p38 MAPK, previously demon-
strated to mediate downstream effects in cardiomyopathy,12 
showed significantly decreased activity on the R60G mutant 
compared to WT LMNA, with a similar trend found for the 
T10I mutant (Figure 8A). However, PKCα, which is known 
to directly interact with lamin A/C,52 did not show signifi-
cant mutation-driven changes in activity. These data support 
kinase- and mutation-specific effects on lamin phosphoryla-
tion, consistent with our in silico prediction.
We explored whether the phosphorylation changes pre-
dicted in silico and observed in vitro might also occur in cells 
expressing mutant lamin A. WT and mutant lamin A were ec-
topically expressed in Huh7 cells, and cells were then treated 
with okadaic acid, a potent phosphatase inhibitor that regu-
lates lamin phosphorylation.53 Immunoblotting of cell lysates 
with both phospho-specific antibodies and an antibody di-
rected to the myc tag (detecting total and transfected lamin A, 
respectively) showed that after treatment with okadaic acid, 
there was an increase in phosphorylation of WT lamin A at 
S22 and S392 as well as an increase in WT lamin A solu-
bility, as shown by an increase in the protein fraction found 
in supernatant (soluble fraction) compared to the pellet (in-
soluble fraction) (Figure 8B). An increase in phosphorylated 
S22 and S392 was also observed after okadaic acid treatment 
with all of the tested lamin A mutants; it should be noted 
that S22 and S392 are thought to be primarily phosphory-
lated by CDK1 rather than p38 or PKC. However, the R60G 
and T10I mutants showed a relative reduction in solubility at 
baseline compared to WT. Importantly, although treatment 
with okadaic acid did increase their solubility somewhat, 
it did not rescue their solubility to WT levels, with a large 
portion of T10I and R60G remaining insoluble after okadaic 
acid treatment (although only the reduced solubility of R60G 
was statistically significant with respect to WT after okadaic 
acid). Notably, no change in R482Q solubility was observed 
relative to WT lamin A either at baseline or with okadaic acid 
treatment.
4 |  DISCUSSION
The precise mechanisms underlying the laminopathies and 
their phenotypic diversity remain obscure. Studies seeking 
to elucidate these mechanisms frequently have been lim-
ited to single mutants, experimental models, or phenotypes. 
While the coexistence of multiple pathways of disease has 
been postulated, holistic approaches seeking to identify spe-
cific modulators of these pathways largely have not been 
explored. The importance of phenotypic clustering and gen-
otype-phenotype correlation in the laminopathies is well es-
tablished.11,16,54,55 Here, we have assembled an updated and 
comprehensive repository of known LMNA variants with 
their associated phenotypes and additional available meta-
data, including mutation status and geographic  origin. We 
then used high-throughput, computational methods to pre-
dict mutation-specific effects on lamin A phosphorylation 
and protein structure with some experimental validation of 
our findings. To our knowledge, this is the most compre-
hensive analysis, classification, and grouping to date of all 
known lamin mutations. Additionally, our novel application 
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of machine-learning methods highlights the potential of 
computational approaches to systematically identify pos-
sible novel mechanisms of disease in genetic disorders, as 
in this case applied to the laminopathies and mutation-spe-
cific predicted phosphorylation and structural contributions. 
Altogether, our findings suggest a potential role for direct 
F I G U R E  7  Predicted LMNA mutation-driven phosphorylation and protein structural changes appear to represent separate processes. A, 
Map depicting LMNA missense mutations, predicted phosphorylation changes, and predicted protein structural changes along the lamin A protein 
backbone. Predicted phosphorylation changes are depicted in shades of orange, with the darker shade representing high confidence predictions 
(see Materials and Methods). Predicted protein structural changes/disruption are shown in shades of green, with darker shades indicating higher 
confidence. Red bars in the discordant row represent amino acid residues at which a missense mutation leads to a predicted change in one property, 
such as phosphorylation, but not the other (eg, a specific mutation leads to a predicted change in phosphorylation without a concomitant change in 
protein structure). B, The distribution of missense mutations depending on discordance reveals greater than half of studied missense mutations lead 
to discordant predictions. A greater proportion of discordant mutations was represented by those with an isolated predicted protein structural change 
than with an isolated predicted phosphorylation change. C, Heatmap depicting relative contribution of changes in phosphorylation (yellow) and 
protein structure (blue), by individual patient, normalized to sample size per phenotype. Brighter colors represent a stronger contribution. Hotspots 
appear as larger, homogenous blocks of color since predictions will not vary among individuals with the same hotspot mutation. D, Summary of panel 
B results showing the average contributions of predicted phosphorylation or protein structural changes for each laminopathy category phenotype
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lamin phosphorylation in the pathogenesis of laminopathies 
with possible therapeutic implications (Figure  9), and can 
serve as a foundation for further experimental exploration of 
specific LMNA mutations.
4.1 | Laminopathy mutation profiles
Analysis of the mutation  data demonstrated patterns in mu-
tation domain, patient sex, and heterozygosity and homozy-
gosity. Laminopathy-associated mutations are mostly of the 
missense type, and affected individuals are typically heterozy-
gous for mutant alleles—the notable exception being those with 
Charcot-Marie-Tooth disease, in which individuals are usually 
homozygous for the LMNA R298C mutation. Predominant 
heterozygosity in the setting of disease presumes dominant in-
heritance of most laminopathies. Rod domain mutations and 
non-missense mutations, particularly nonsense and frameshift 
mutations, are found most commonly in striated muscle lami-
nopathies. In contrast, tail mutations are commonly associated 
with lipodystrophy-type disorders such as FPLD and MAD.
These key differences suggest separate or even dichot-
omous mechanisms underlying these different phenotypes. 
For instance, the higher prevalence of non-missense mu-
tations in muscle laminopathies suggests that, relative to 
missense mutations, these mutation types may be overall 
more disruptive to protein structure and more significantly 
impair tissue tolerance to mechanical stress. Similarly, 
missense mutations that are predicted to more likely dis-
rupt protein structure (ie, occurring within the rod domain) 
are more prevalent in striated muscle laminopathies. In 
contrast, lipodystrophies and MAD are characterized by 
missense mutations in the tail domain. Importantly, the af-
fected tissues in these diseases (adipose, bone, skin) are 
exposed to less mechanical stress compared to muscle, im-
plying an alternative underlying mechanism.
Analysis of amino acid changes among laminopathy-asso-
ciated missense mutations revealed patterns similar to those 
previously noted in keratins.56 For example, keratins have a 
relative scarcity of native cysteine and histidine residues, yet 
de novo cysteine or histidine introduction is seen in a signif-
icant proportion of disease-associated keratin mutations. This 
also appears to be the case in lamins, suggesting that cysteine 
or histidine may result in a “toxicity” that affects higher-order 
structure formation though, under in vitro purified protein con-
ditions, the keratin 14 mutant R125C is able to form extensive 
filaments.57 In addition, proline was the most common mutant 
residue among laminopathy-associated missense mutations 
(Figure  3). Interestingly, mutations resulting in a change to 
proline almost exclusively result in disease involving striated 
muscle, which invokes a common underlying mechanism. The 
addition of a proline can significantly alter protein structure 
given its conformationally rigid cyclic side chain; however, 
proline is also implicated in phosphorylation via proline-di-
rected kinases, which target Ser/Thr that precede proline res-
idues and encompass MAP kinases and CDKs. This could 
explain in part the efficacy of MAPK inhibitors in lamin-asso-
ciated cardiomyopathies.12-14
A deeper investigation of mutational patterns among the 
heptad repeats of the coiled-coil domain revealed that the e 
and g positions within the heptad were more likely to be mu-
tated than other positions. A recent study illustrated that mu-
tations causing L-CMD were more likely to be at the a d e g 
positions, which are critical for stabilizing lamin polymers.29 
Here, we observed a relative predilection for skeletal muscle 
laminopathies to involve residues at the e position, whereas 
primary cardiac phenotypes showed a more even distribu-
tion. While this requires further exploration, it could indicate 
F I G U R E  8  The disease-associated R60G mutation alters LMNA phosphorylation in vitro and reduces LMNA solubility. A, Huh7 
cells were transfected with myc/DDK-tagged wild-type (WT) LMNA or the indicated LMNA mutant, then harvested in RIPA buffer 
followed by immunoprecipitation of LMNA using antibodies directed against the myc/DDK tag. Top left panel, WT and mutant LMNA were 
immunoprecipitated from cell lysates and analyzed by SDS-PAGE followed by immunoblot; tagged LMNA is indicated with an arrow. The 
immunoglobulin heavy chain (IgH) is labeled, and a nonspecific band is indicated via arrowhead. Top right panel, in vitro phosphorylation of 
immunoprecipitated LMNA was carried out using recombinant p38 (top) or PKCα (bottom) followed by SDS-PAGE and autoradiography;  
32P signal corresponding to myc/DDK-LMNA is indicated by an arrow, with an arrowhead indicating a nonspecific band. Bottom panels, 
32P-LMNA signal was quantitated relative to LMNA input using ImageJ software. Data shown were derived from n = 3 independent experiments, 
and error bars represent standard error of the mean (SEM). Pairwise comparison using Student’s t test was used to determine statistical 
significance; *P < .05. B, Top panels, Huh7 cells were transfected with myc/DDK-tagged WT LMNA or the indicated LMNA mutant, treated 
with 500 nM okadaic acid for 1 hour at 37°C where indicated, and harvested in 1% Triton X-100 lysis buffer containing protease and phosphatase 
inhibitors. The Triton-insoluble pellet was then boiled in SDS buffer, and Triton-soluble and insoluble (pellet) fractions were analyzed by SDS-
PAGE followed by immunoblot using the indicated primary antibodies. Coomassie-stained gels are shown to demonstrate equal protein loading.  
Myc/DDK-tagged LMNA is indicated via arrow; arrowhead indicates a nonspecific band. Bottom panels, the soluble proportion of tagged 
LMNA was quantitated via ImageJ relative to WT LMNA under basal conditions, with WT LMNA under basal conditions arbitrarily set to 1.0. 
Data shown were derived from n = 3 independent experiments, and error bars represent standard error of the mean (SEM). For each condition 
(basal and okadaic acid-treated), paired Friedman ANOVA was performed to compare WT to mutant LMNA, followed by uncorrected Dunn’s 
test for multiple comparison adjustment to determine statistical significance; *P < .05. MW, apparent molecular weight; kDa, kilodaltons; IP, 
immunoprecipitate
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F I G U R E  9  Proposed phosphorylation-related laminopathy disease mechanisms. Left: Global changes in phosphorylation occur in response 
to possible mutation-induced protein misfolding and aggregate formation, with subsequent alterations of dynamic filament assembly and nuclear 
morphology. This leads to decreased tolerance to cell-specific stress, such as mechanical and oxidative stress, which activates downstream stress-
induced kinases such as ERK, mTOR, p38, and JNK. A phosphorylation-mediated signaling cascade ultimately results in altered gene expression, 
which leads to cell-specific phenotypes. Selective pharmacologic inhibitors against these stress-induced kinases are shown; previous studies have 
demonstrated attenuation of disease effects in cardiomyopathy and progeria models using such inhibitors. ARRY-371797 is currently in clinical 
trials for cardiomyopathy in humans. Chemical chaperones, which can stabilize native conformations of proteins (or reduce pathogenic misfolding/
aggregation), may have a role in laminopathies, but this has not been reported. Right: Lamin mutations lead to specific alteration of kinase-
binding motifs on lamin itself, which leads to several downstream effects, including altered protein-protein interactions, altered lamin localization 
(eg, an increased ratio of nucleoplasmic-to-nuclear envelope lamin), and effects on lamin-chromatin/DNA interactions (eg, lamin-associated 
domains). These could all lead to alterations in gene expression. Notably, protein and DNA interactions are likely cell specific and may influence 
the specific phenotype observed. Other PTMs affected by mutations may also have an impact, with potential crosstalk between different PTMs. 
ERK, extracellular signal-related kinases; JNK, c-Jun N-terminal kinases; LAP2α, lamina-associated polypeptide 2α; mTOR, mammalian target of 
rapamycin; p38, p38 mitogen-activated protein kinases; Rb, retinoblastoma protein
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a pathomechanical basis for skeletal muscle disorders that 
could distinguish them from cardiac disorders.
Mutational patterns were largely driven by hotspot muta-
tions, which frequently resulted in phenotypes involving mul-
tiple organ systems. Interestingly, comparing hotspot with 
non-hotspot mutations revealed a disproportionate number 
of cytosine to thymine transitions, which relates to a known 
phenomenon in which CpG dinucleotides are especially 
prone to mutation. This is due to vulnerability of cytosine to 
deamination, the frequent methylation of cytosine in CpG di-
nucleotides, with deamination of 5-methylcytosine resulting 
in thymidine.58 The vulnerability of these sites to mutation is 
responsible for the frequency of mutation in native arginine 
residues, given the high prevalence of cytosines within co-
dons for arginine.
Several LMNA mutations lead to either overlapping 
syndromes or disparate phenotypes, in which a single mu-
tation can lead to different organ system involvement in 
two different individuals. A curious example is the R644C 
mutation, which can lead to a wide array of disparate phe-
notypes including all major categories of laminopathies 
(progeria, neuropathy, striated muscle laminopathy, and 
lipodystrophy). This particular mutation also notably has 
an extremely low degree of penetrance, with only 31 of 186 
(16.7%, which includes healthy individuals from the ExAC 
database) patients developing disease. The pleiotropy of 
such mutations suggests the presence of other modifiers, 
possibly spanning genetic, epigenetic, and post-transla-
tional realms, that modulate the development of a specific 
phenotype. For example, lamin A has numerous binding 
partners including nucleoskeleton proteins (eg, Nesprin 2 
and Nup88), transcription factors (eg, Rb and SREBP1 
a/c), kinases (eg, PKCα), and chromatin.1,59,60 The pres-
ence of these binding partners varies based on tissue type 
and, similarly, phosphorylation sites and states appear to 
depend on the specific cell or tissue type studied.6 Since 
many of these binding partners appear to bind to the tail 
domain, it is possible that the overlapping and disparate 
phenotypes associated with a lamin A mutant like R644C 
(and several others in the tail region) may be due to vari-
able binding of tissue-specific binding partners.
4.2 | Crosstalk between lamin 
mutation-modulated phosphorylation and 
structural effects
PTMs likely impact disease mechanisms in a mutation-spe-
cific way. For example, previous studies have demonstrated 
a link between FPLD-associated mutations and disruption of 
lamin A SUMOylation.59,61,62 More recent studies have im-
plicated loss of O-Glc-NAcylation to be associated with mu-
tations resulting in HGPS.63 Moreover, lamin A/C classically 
undergoes several important physiologic PTMs such as tran-
sient farnesylation, which allows lamin to initially associate 
with the inner nuclear membrane, and proteolytic cleavage 
into its mature form by ZMPSTE24. In HGPS, lamin A/C 
is unable to undergo this final cleavage step, resulting in 
permanent farnesylation. This has led to testing the use of 
farnesyltransferase inhibitors in the treatment of HGPS.64 It 
is also thought that various PTMs may facilitate PTM cross-
talk, which may also regulate protein function.5
Our findings demonstrate a significant correlation between 
disease and predicted mutation-induced changes to lamin 
phosphorylation and structure (Figures 6 and 7). Importantly, 
phosphorylation changes occurred predominantly in the head 
and tail domains of lamin A/C (Figure 6B), which are the do-
mains that typically harbor physiological phosphorylation for 
IFs in general.65 A limitation of our computational methods 
is that they are only able to make predictions on phosphory-
lation changes that are proximal to the given mutation (±16 
or 25 amino acid residues in MIMP and MusiteDeep, respec-
tively) and cannot account for more distant effects that may 
occur due to protein folding. Therefore, it is possible that our 
approach will underestimate long-range mutational effects on 
phosphorylation.
Segregation of predicted phosphorylation and struc-
tural changes by phenotype demonstrated key differences, 
implicating possible phenotype-specific mechanisms of 
disease. Specifically, lipodystrophy and bone/skin pheno-
types were associated with predicted changes in phosphor-
ylation, while this was significantly less likely in striated 
muscle laminopathies, which were much more likely to 
be associated with structural change (Figure 6C). Hotspot 
mutations were more likely to be associated with changes 
in phosphorylation, but the same trend was not observed 
among predicted structural changes (Figure 6D,E). While 
it is possible that these findings may reflect a preferred lo-
calization of these disease mutations in the lamin protein 
without direct pathophysiological relevance, it could also 
suggest two nonmutually exclusive alternative mechanisms 
by which mutations can lead to disease by: (i) directly dis-
rupting lamin protein structure and organization, or (ii) in-
ducing changes in phosphorylation.
In vitro assessment of mutation-associated changes in 
lamin phosphorylation revealed both kinase- and muta-
tion-specific changes (Figure 8). Utilizing an in vitro kinase 
assay with p38 MAP kinase indicated a decrease in phosphor-
ylation in the T10I and R60G mutants (although only R60G 
was statistically significant) but not R482Q; in contrast, 
PKCα showed no significant changes across the mutants. 
Of note, lamin A/C contains more than 10 predicted PKCα 
sites, which limits the sensitivity of such an assay to detect a 
decrease in lamin phosphorylation. In addition, protein phos-
phorylation may impact protein conformation and solubility. 
We observed a significant reduction in baseline solubility 
9070 |   LIN et aL.
of the T10I and R60G mutants relative to WT lamin A, and 
these mutants remained largely insoluble relative to WT after 
treatment with okadaic acid, a potent phosphatase inhibitor, 
even though phosphorylation of residues S22 and S392 could 
be detected for all mutants. These data suggest that the T10I 
and R60G mutants are relatively resistant to hyperphosphor-
ylation, given that treatment with okadaic acid leads to global 
hyperphosphorylation.
Notably, T10I was predicted to be associated with loss 
of phosphorylation by our computational approach, while 
R60G was predicted to be associated with possible loss (only 
MusiteDeep predicted a loss). In contrast, neither T10I nor 
R60G were predicted to induce significant structural changes 
to lamin A/C, although our predictions do not consider ef-
fects beyond the monomeric form of the protein and thus do 
not preclude downstream effects on aggregate formation that 
could affect solubility (eg, relative insolubility could reflect 
aggregation or an unaggregated insoluble pool). In this re-
spect, it is possible that phosphorylation of specific amino 
acid residues may have an impact on lamin polymer assembly.
Furthermore, while R482Q was predicted to be associated 
with a loss of phosphorylation, we did not observe a change in 
R482Q phosphorylation, and there was no noted change in sol-
ubility relative to WT lamin A/C. It is possible that solubility 
changes may be induced by phosphorylation in specific regions 
of the protein, such as the coiled-coil rod domain, while phos-
phorylation affecting tail regions may not have a similar effect. 
Interestingly, T10I is associated with progeroid syndromes, 
R60G with striated muscle laminopathies, and R482Q with li-
podystrophy—again suggesting possible distinct mechanisms.
Further studies are needed to elucidate the precise phos-
phorylation sites that are altered in the setting of lamin 
mutations, as well as specific downstream effects that 
likely extend beyond protein conformation and solubility. 
To date, studies on lamin phosphorylation have focused 
on its role in cell cycle regulation, specifically phosphor-
ylation of S22 and S392 during mitosis.9,10 Previously, 
stress-induced kinase inhibition was shown to ameliorate 
the effects of lamin-associated cardiomyopathy and proge-
ria  in experimental model systems.11,12,14,17,18 Our results 
suggest that the impact of kinase inhibitors likely reflects 
downstream phosphorylation-mediated effects that may be 
secondary to structural changes in the lamin A/C protein 
affecting polymerization, nuclear assembly, and tolerance 
to mechanical stress, as shown in Figure  9. In addition, 
our findings demonstrate that an alternative phosphory-
lation-mediated pathway—direct lamin A/C phosphoryla-
tion—by itself directly associates with disease. Alterations 
to lamin A/C phosphorylation may specifically be involved 
in certain phenotypes, such as lipodystrophy, which have 
previously not been as amenable to stress-induced kinase 
inhibition. Mutations leading to changes in lamin A/C 
phosphorylation may have a myriad of downstream effects, 
including changes in localization, protein-protein interac-
tions, lamin-chromatin interactions, and downstream sig-
naling cascades.10 This ultimately leads to changes in gene 
expression, which likely represents a common downstream 
effect among the different phosphorylation-mediated path-
ways (Figure 9).
4.3 | Therapeutic implications
Distinct phosphorylation-mediated mechanisms of disease sug-
gest the need for more than a one-size-fits-all approach. Previous 
studies demonstrating the benefits of stress-induced kinase inhi-
bition have focused on the cardiomyopathy and progeria phe-
notypes, with a small number of mutations representing each 
phenotype studied.11,15,16,18,19,66 Current clinical trials include 
only ARRY-371797, a p38 inhibitor, in the context of LMNA-
related dilated cardiomyopathy (ClinicalTrials.gov). In some 
cases, kinase activation can also be beneficial. A recent study 
examining the interaction between prelamin A or mature lamin 
A/C with CK2 demonstrated that both prelamin A and mature 
lamin A/C inhibit CK2 via binding to its enzymatic core subu-
nit, inducing early cellular senescence. Meanwhile, activation of 
CK2 with a small molecule spermidine conferred resistance to 
senescence and ameliorated progeroid features with extension of 
lifespan in mice.67 Our computational predictions also indicate 
mutation-dependent increases or decreases in phosphorylation, 
which further highlights the likely need for tailoring therapies 
depending on the precise mutation and phenotype in question.
Continued investigation elucidating the downstream 
pathways triggered by differential lamin phosphorylation 
may reveal additional therapeutic targets. For example, 
stress-induced kinase activation likely results from mechan-
ical stress due to lamin mutation-induced structural alter-
ations, which offers another opportunity for intervention 
at the protein folding step (Figure  9). For example, in the 
skin fragility disorder epidermolysis bullosa simplex (EBS), 
treatment with 4-phenylbutyrate, a chemical chaperone, de-
creased keratin aggregation and reduced inflammation in a 
culture system.68,69 Given evidence that multiple subtypes of 
laminopathy present with protein aggregation,1,70-72 the use 
of chemical chaperones could provide a novel approach to 
laminopathy treatment.
Collectively, our findings suggest a role for direct lamin 
phosphorylation as a mutation-dependent and kinase-depen-
dent modifier of tissue-specific defects and subsequent lami-
nopathy phenotypes. Current therapeutic approaches may be 
limited to certain mutations or associated phenotypes, and thus 
may not fully encapsulate the myriad mechanisms of disease 
that are apparent in the laminopathies. This highlights the need 
to elucidate alternative disease mechanisms in order to con-
struct specific, personalized treatment strategies. Here, we have 
re-purposed machine-learning–based computational methods 
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in a rare genetic disease, demonstrating the capability of these 
methodologies for generating hypotheses about mechanisms of 
disease.
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